Jaguar Health, Inc. (NASDAQ:JAGX) Sees Significant Increase in Short Interest

Jaguar Health, Inc. (NASDAQ:JAGX) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 353,400 shares, an increase of 8.7% from the May 31st total of 325,100 shares. Currently, 8.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,070,000 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Jaguar Health from a “hold” rating to a “sell” rating in a research note on Monday, June 24th.

Jaguar Health Stock Performance

NASDAQ:JAGX opened at $3.41 on Wednesday. Jaguar Health has a fifty-two week low of $3.07 and a fifty-two week high of $41.76. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.89 and a quick ratio of 1.39. The business has a 50 day moving average price of $8.38 and a 200-day moving average price of $7.02.

Jaguar Health (NASDAQ:JAGX) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($3.60) earnings per share for the quarter. The company had revenue of $2.35 million for the quarter. Jaguar Health had a negative net margin of 377.95% and a negative return on equity of 642.15%. Equities analysts forecast that Jaguar Health will post -5.42 earnings per share for the current year.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.